We organized a webinar named “Innovative Approaches to Drug Repositioning: The Cloudscreen® Platform” where our one-stop-shop drug repurposing platofrm was presented.
Cloudscreen Presentation
Category: Pharma
Drug repurposing, Big Data & Artificial Intelligence
Lay science article about drug repurposing published in InScience Magazine. Drug repurposing significantly accelerates the discovery and development of drugs with a substantial impact on rare diseases. In collaboration with big data and artificial intelligence (AI) technologies, it enhances the reliability of predictions, regarding the effectiveness, but also the toxicity of the repurposed drug. Modern computational tools now guide and enrich laboratory approaches, while the latter validate working hypotheses or create new ones. A typical example of innovative synergies is the drug repositioning platform Cloudscreen©, an innovation product of Cloudpharm PC, a Greek start-up company, and the Biomarker Discovery & Translational Research Laboratory of the National Research Foundation.
Presenting Cloudscreen at the Repo4EU on tour event in Athens
Repo4EU is an EU funded project with the aim of building the Euro-Global Platform for Mechanism-based Drug Repurposing. Learn more here
Through the course of the Repo4EU national dissemination journey, at their stop in Greece we were invited to present our repurposing platofrm CLOUDSCREEN.
Cloudscreen at Pfizer’s Start4Health challenge
Posters presentations at EACR 2022 Congress – Innovative Cancer Science: Translating Biology to Medicine
Modelling missense mutations on druggable proteins for computational drug repurposing
Poster presenation at the International E-conference on Bioinformatics 2022
“Research – Create – Innovate” Projects
“Research – Create – Innovate” Projects AT NHRF
Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine
Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine
Abstract
Aberrant angiogenesis is a hallmark for cancer and inflammation, a key notion in drug repurposing efforts. To delineate the anti-angiogenic properties of amifostine in a human adult angiogenesis model via 3D cell metabolomics and upon a stimulant-specific manner, a 3D cellular angiogenesis assay that recapitulates cell physiology and drug action was coupled to untargeted metabolomics by liquid chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. The early events of angiogenesis upon its most prominent stimulants (vascular endothelial growth factor-A or deferoxamine) were addressed by cell sprouting measurements. Data analyses consisted of a series of supervised and unsupervised methods as well as univariate and multivariate approaches to shed light on mechanism-specific inhibitory profiles. The 3D untargeted cell metabolomes were found to grasp the early events of angiogenesis. Evident of an initial and sharp response, the metabolites identified primarily span amino acids, sphingolipids, and nucleotides. Profiles were pathway or stimulant specific. The amifostine inhibition profile was rather similar to that of sunitinib, yet distinct, considering that the latter is a kinase inhibitor. Amifostine inhibited both. The 3D cell metabolomics shed light on the anti-angiogenic effects of amifostine against VEGF-A- and deferoxamine-induced angiogenesis. Amifostine may serve as a dual radioprotective and anti-angiogenic agent in radiotherapy patients.
Drug repurposing in Glioblastoma Multiforme
Drug repurposing in Glioblastoma Multiforme
Poster presenation at 1st ESN-ISN School “FROM NEURODEGENERATION TO NEURAL CARCINOGENESIS: MECHANISMS AND COMMON BIOLOGIES” and the 10th International Hellenic Crystallographic Association Conference
Proteogenomics for drug repurposing
PROTEOGENOMICS PROFILING OF THE 3D CELL MICROENVIROMENT FOR DRUG REPURPOSING
Poster presentation at the EMBO practical course “TARGETED PROTEOMICS-EXPERIMENTAL DESIGN AND DATA ANALYSIS”
